Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients

Bibliographic Details
Main Authors:	Angelo Maiolino, Elaine Sobral Da Costa, Alberto Orfao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Oncology
Subjects:	minimal residual disease multiple myeloma prognostic factor disease monitoring flow cytometry
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1211935/full

Similar Items

Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium
by: Agnieszka Krzywdzińska, et al.
Published: (2021-10-01)

FLOW CYTOMETRY IN THE DIAGNOSIS AND MONITORING OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA
by: I. V. Galtseva, et al.
Published: (2017-06-01)

STUDY OF MINIMAL RESIDUAL DISEASE BY MULTICOLOR FLOW CYTOMETRY IN MULTIPLE MYELOMA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
by: I. V. Galtseva, et al.
Published: (2017-06-01)

Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma
by: Jing Wang, et al.
Published: (2024-02-01)

Minimal Residual Disease in Multiple Myeloma—Current Approaches and Future Clinical Implications
by: Theresia Akhlaghi, et al.
Published: (2022-07-01)

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
by: Noemí Puig, et al.
Published: (2021-09-01)

Minimal Residual Disease in Multiple Myeloma: Something Old, Something New
by: Carlos Bravo-Pérez, et al.
Published: (2021-08-01)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
by: Ioannis V. Kostopoulos, et al.
Published: (2020-05-01)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
by: Alessandro Gozzetti, et al.
Published: (2020-09-01)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
by: Katharina Kriegsmann, et al.
Published: (2020-08-01)

Consensus for Flow Cytometry Clinical Report on Multiple Myeloma: A Multicenter Harmonization Process Merging Laboratory Experience and Clinical Needs
by: Iole Cordone, et al.
Published: (2023-03-01)

Flow Cytometric Analysis of Bone Marrow Particle Cells for Measuring Minimal Residual Disease in Multiple Myeloma
by: Duanfeng Jiang, et al.
Published: (2022-10-01)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
by: Roberto Mina, et al.
Published: (2020-07-01)

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma
by: Mo Zhou, et al.
Published: (2024-03-01)

Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity
by: Kazuhito Suzuki, et al.
Published: (2021-09-01)

B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients
by: Robéria Mendonça de Pontes, et al.
Published: (2021-04-01)

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
by: Elena Zamagni, et al.
Published: (2020-10-01)

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma
by: Konstantinos Papadimitriou, et al.
Published: (2020-11-01)

Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?
by: Joana Caetano, et al.
Published: (2022-06-01)

Steps towards a Multiple Myeloma Cure?
by: Alessandro Gozzetti, et al.
Published: (2022-09-01)

Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma
by: Hareth Nahi, et al.
Published: (2023-11-01)

Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
by: Giuseppe Bertuglia, et al.
Published: (2022-12-01)

Minimal residual disease negativity by next‐generation flow in non‐CR myeloma patients
by: Sung‐Min Kim, et al.
Published: (2020-11-01)

Minimal residual disease in plasma cell (multiple) myeloma: flow cytometric approaches
by: L. Yu. Grivtsova, et al.
Published: (2020-04-01)

Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment
by: Kazuhito Suzuki, et al.
Published: (2023-04-01)

Liquid biopsies and minimal residual disease in lymphoid malignancies
by: Maroun Bou Zerdan, et al.
Published: (2023-05-01)

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
by: Valeria Ferla, et al.
Published: (2022-08-01)

Flowcytometric and DNA Analysis Minimal Residual Disease (MRD) in Childhood B-Lineage lymphoblastic leukemia
by: Vossough P, et al.
Published: (2005-07-01)

Flowcytometric and DNA Analysis Minimal Residual Disease (MRD) in Childhood B-Lineage lymphoblastic leukemia
by: P Vossough, et al.
Published: (2005-06-01)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
by: Paola Pacelli, et al.
Published: (2022-11-01)

Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil
by: Anna Beatriz dos Santos Salgado, et al.
Published: (2023-03-01)

O valor da imunofenotipagem para o diagnóstico do Mieloma Múltiplo e na avaliação da doença residual mínima The value of immunofenotyping for the diagnosis of Multiple Myeloma and for the evaluation of minimal residual disease
by: Roberto P. Falcão, et al.
Published: (2007-03-01)

Hematopoietic stem cell transplantation in the treatment of multiple myeloma
by: Angelo Maiolino
Published: (2002-01-01)

Label-Free Enrichment of Circulating Tumor Plasma Cells: Future Potential Applications of Dielectrophoresis in Multiple Myeloma
by: Nicolò Musso, et al.
Published: (2022-10-01)

Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment?
by: Mattia D’Agostino, et al.
Published: (2023-07-01)

STANDARDIZATION OF FLOW CYTOMETRIC MINIMAL RESIDUAL DISEASE MONITORING IN CHILDREN WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. RUSSIA–BELARUS MULTICENTER GROUP EXPERIENCE
by: A. M. Popov, et al.
Published: (2017-01-01)

Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease
by: Sébastien Gouard, et al.
Published: (2020-09-01)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: Elena Zamagni, et al.
Published: (2020-12-01)

Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview
by: Slavisa Ninkovic, et al.
Published: (2020-11-01)

Flow cytometry in the diagnosis of plasma cell tumors and assessment of minimal residual disease
by: L. Yu. Grivtsova, et al.
Published: (2021-09-01)